Dr. Julian Zachmann

Investment Manager

Dr. Julian Zachmann

Investment Manager

As a senior scientist in computational drug discovery, Julian Zachmann has successfully guided an anti-cancer drug through preclinical studies within 2 years. He then founded his own start-up in the field of Artificial Intelligence / Digital Health and subsequently completed an MBA at INSEAD. Since 2019 Julian has been working in the Life Science Team at HTGF and is very interested in artificial intelligence applications.


+49 – (0) 228 – 82300 – 166


Posts & mentions

7. June 2022

Invasight closes CHF 4.5 million oversubscribed seed round

The funds will accelerate the development of targeted therapies with superior safety profile for patients with invasive cancers. Zurich, Switzerland, 7 June 2022 – Invasight AG, a Swiss pre-clinical stage biotech company with a mission to develop their breakthrough targeted therapies for invasive cancers, announced the closing of a CHF 4.5 million seed round. The seed financing round was led by OCCIDENT and co-led by JFG Life Sciences Foundation, with participation from Verve Ventures,
5. July 2021

Cutanos closes first financing round with investor consortium from Austria and Germany

Max Planck spin-off develops immunotherapies through innovative platform technology Vienna, July 5 2021 - Cutanos GmbH, a Viennese biotech start-up, announces the successful closing of its first financing round with KHAN Technology Transfer Fund I (KHAN-I), High-Tech Gründerfonds (HTGF), IST cube and another private investor. Cutanos was founded in early 2021 as a spin-off of the Max Planck Institute of Colloids and Interfaces. The core of the company is its Langerhans Cell Target Del
16. December 2020

An international pool invests ~ 2 Mio € in mediaire, the preventive medicine start-up "Made in Germany"

HTGF, primeCROWD and LIFTT are part of an international round for the development of “Deep learning diagnostic” which allows faster, more accurate and safer MRI analysis. Expansion into European markets will start in 2021 accompanied by a significant expansion of product portfolio  mediaire, the start-up born in Berlin in 2018 that has proprietary disruptive technologies in the field of magnetic resonance imaging (MRI), aims at international markets thanks to a joint investment m
28. August 2020

Aignostics raises €5m Seed Round to advance AI-powered pathology

Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, pioneering computational pathology for pharmaceutical research and diagnostics, has announced today the closing of €5m in seed round funding. Boehringer Ingelheim Venture Fund (BIVF) led the round, with participation from the High-Tech Gründerfonds (HTGF), VC Fonds Technologie der IBB Beteiligungsgesellschaft, and Future Capital. Aignostics formally started out in early 2018, when r


14. July 2022
Wildcard Challenge 2022
You have a well-founded idea for a start-up? Your idea comes from the field of life sciences (biotechnology, medical technology, pharmaceuticals, etc.)? You want to further develop your idea with excellent coaches and get critical feedback? On July 14, 2022 the Wildcard Challenge 2022 will take place at the Life Science Factory in Göttingen. There, exciting start-up ideas will be discussed and further developed. HTGF is participating as a partner in this project. Dr. Laura Pedroza and Dr. Julia